Rani Therapeutics announced its financial results for Q4 and full-year 2025, highlighting a $1.085 billion collaboration with Chugai Pharmaceutical to develop oral therapies using its RaniPill® platform. The company reported successful preclinical data for oral delivery of semaglutide and RT-114, a dual GLP-1/GLP-2 agonist, and initiated a Phase 1 trial for RT-114 targeting obesity. Rani raised $60.3 million in a private placement, repaid all outstanding debt, and ended 2025 with $49.7 million in cash and securities, expecting to fund operations into late 2027. These developments position Rani to advance oral biologic therapies and expand partnerships in high-value therapeutic areas.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
AmpliTech Group marked its fifth anniversary as a public company by ringing the Nasdaq opening bell and announcing record revenue of $25.2 million in fiscal 2025, a 165% increase year-over-year. The company, a US-based leader in RF and microwave sign...
